Hello and welcome to today's webcast on the second quarter 2024 financial report of Ex Brain Biopharma. Uh, my name is Martin. I'm the CEO and I also have our CFO, Annette Lindquist, with me today. We will go through a brief presentation highlighting the operational advances during the past quarter and also the financials. And we will take questions thereafter. You can ask questions both via audio and also via the chat. Uh, and we'll do our best to answer them. Um, so let's start off here. Most of you who are calling in probably know what we are engaged in. We are biosimilar developers. So, we're developing biosimilar drugs to be approved as replacements for biologics, which can be launched post-patent expiration or loss of exclusivity of the respective originator products. Our portfolio consists of four biosimilars and biosimilar candidates. Ximluci is approved as a biosimilar to Lucentis in Europe and has been launched since the first quarter of 2003 by our commercialization partner, Strada. We are going through a regulatory process with the FDA for US approval, and we have partnered up with Valorem Biologics to commercialize the product in the US post-approval. We are developing biosimilar candidates for CMC and Opdivo, respectively, both of which are in the late pre-clinical stage. We have scaled up the respective production processes, and we are currently engaged in a very active licensing process to find a suitable commercialization partner for these two biosimilar candidates so that we, together with a partner, can proceed into clinical development. Then we have the early preclinical development of a biosimilar candidate for Dorzalex. All in all, this portfolio is addressing a market based on the originator's peak sales estimate combined of €26 billion. So we're looking at the seamless integration said Lucy Forester. We can take a snapshot of the retinal anti-VEGF market outside of the US for retinal disorders. So, this is a market of about, um, a little bit north of €5 billion in annual net sales. You can see in the graph on the left-hand side, the light blue bars represent Lucentis, the originator product, which is a biosimilar. The red bars, advancing on top, are the Lucentis biosimilars approved in Europe. We are observing that biosimilars are gradually gaining market share, which, for those of you who have followed us, has taken more time than we initially anticipated. However, we are seeing movement in the right direction with the gradual market share gain of the Lucentis biosimilars. We remain steadfast in our view. At the initiation of this development, we believed that, at the end of the day, these biosimilars would take approximately 70% volume market share of the overall randomized market. And to clarify, the active ingredient in Lucentis is called Ranibizumab. Over a couple of years, that's what we've seen for biosimilars that have entered in relation to other molecules or biological drugs, particularly in the oncology and immunology space. So, that's still the outlook we believe in. Of course, we believe that the exclusive shall be a preferred choice among respective biosimilars to Lucentis, and taking a snapshot of where we stand together with our partners when it comes to the commercialization process. Christmas is now celebrated across 18 countries. So, there's a gradual launch in additional countries. As you can see, from a value market share perspective, we're well above 1% now. This is a quarterly market, if you only look at the retinal anti-VEGF market. Lucentis plus the Lucentis biosimilars have about €300 million in quarterly sales. And this is now for the second quarter of 2024. It seamlessly took well above 1% of that market. And also ranks as the second among the Lucentis biosimilars. It's up against biosimilars commercialized by Novartis and Roche, respectively. As I said, Ximluci is number two. We're happy to note that the net sales of Ximluci showed strong growth in the second quarter, close to 40%, in net sales versus the first quarter of 2024.
We're happy to see that this was partly driven by continued volume growth, as you can see in the graph. On the bottom side, on the right-hand side here, that's kind of depicting the volume growth quarter by quarter in the last quarter. We've been between 20 to 30% in volume growth. There was a 21% volume growth in the second quarter of 2024 versus the first quarter of 2024, but the 40% growth in net sales. So that, of course, included a mixed effect which impacted the average selling price positively.
And that is stronger growth in markets where the price is a bit higher than in other markets, essentially. So we're happy to see that development. And we are working relentlessly together with our partners to ensure the successful continued commercialization of this product in Europe. And continue the development exclusively. As you might recall, we unfortunately received a complete response letter from the FDA on our initial biologics license application. And that was in April this year. We held a longer webcast in relation to that complete response letter.
It mainly centered around issues with the reference standard, which we planned to use for the release of the product for the US market, as well as observations in pre-approval inspections done by the FDA at the respective manufacturing sites. Where the product is planned to be produced for the US market. We are now going through a process of qualifying a new reference standard, we've had a meeting with the FDA on that topic and agreed on a strategy.
And exactly how we're going to ensure full alignment with the agency around the qualification of the new reference standard. And we are also working together with our respective contract manufacturers to resolve the observations which they had on their respective sites and, as previously communicated, we're targeting a resubmission of the biologics license application in the fourth quarter of this year. It's a standard six months review process for a resubmitted biologics license application. So we're expecting a decision date in the second quarter of 2025. We're also working, as you know, on the prefilled syringe of Ximluci to be launched initially in Europe. And we hope, of course, that this preferred syringe can subsequently be introduced to the US market. But initially it's about the European market and we're preparing for submission. This essentially represents a variation to the existing approval for provider authorization, of course. A launch in Europe in 2025, as you know, is currently approved and commercialized as a vial.
Whereas the originator, Lucentis, by and large, is sold with a prefilled syringe. The two presentations are prevalent on the market. However, the prefilled syringe is the predominant form. There is a certain time-saving benefit in clinics, which makes the prefilled syringe the more convenient choice for ophthalmologists.
Therefore, we do believe that the introduction of the prefilled syringe will unlock further market opportunities and lead to an upswing in sales across Europe. That's our expectation. So, that was briefly about Ximluci, and moving on to our biosimilar candidate CMC. It's now called Exp 003. Here we worked during the second quarter and the summer months on scaling up the production process on the drug substance side with our selected contract manufacturer, and we can happily announce that we've been successful in that.
We have now successfully scaled up the production process to a suitable scale to enter clinical development. We have confirmed the analytical similarity to the reference product in the same manner as we did at the small scale, as you may have noted if you followed us over the summer. Unfortunately, we regained the rights to this program from Bayer, and we had a partnership a few years back with Bayer around this product. They underwent a strategic review of their full portfolio, and several circumstances on their end led to their decision to terminate this license agreement with us, and hence the full rights to this program have been returned to us.
Immediately after receiving that notice from Bayer, we started the licensing process to find a suitable commercialization partner for the program to support us in the upcoming clinical development. We have engaged an advisory firm in this effort, and we're working with the same life science advisory firm, both when it comes to licensing of Exp 003, as well as the Xtrain biosimilar candidate. We had, prior to the termination of the agreement with Bayer, received quite a lot of incoming interest around this program. We believe it's a unique program as it's one of only a few biosimilars under development globally.
Moreover, it's still a sizable originator product with approximately €2 billion in annual sales. We believe we have a unique proposition when it comes to providing this at what we believe are commercially viable production costs, thanks to our platform technology. This gives us high productivity in the production process of this specific molecule. I think we have continued strong interest in this licensing process. We are running on a tight timeline.
We are trying to conclude a license agreement before the end of October. This goes both for Series three as well as Xtrain. What we are also focused on now is incorporating into the program the development activities which were previously under Bayer's responsibility, which basically involves preparing for upcoming scientific advice with the EMA and FDA to agree on the clinical development plan as well as the drug product side of the whole development. These are also areas where we expect that the future commercialization partner will support us. In any case, the program is prepared for and ready to go into the clinic in 2025. So, just briefly on item 003. Um, and sorry if we move here to, um, Ximluci, our, um, Opdivo biosimilar candidate. As noticed, these two programs are proceeding pretty much in parallel right now. We have also successfully scaled up the production process together with the selected contract manufacturer and confirmed the analytical similarity profile versus the reference product. We also, as we communicated in a press release not long ago, received positive feedback from the EMA and in the scientific advice we had with them. We essentially got an acceptance on our proposed clinical development plan, which entailed a streamlined approach. And we believe this is crucial, actually, in order to be successful with this program. As those of you who follow this market know, what is currently required from a regulatory guideline perspective is to conduct both a Phase One and a Phase Three trial for biosimilar candidates. In these trials, you compare pharmacokinetics in the Phase One, and the biosimilar versus the reference product on a well-selected efficacy endpoint in a Phase Three trial. Now, for this particular program, and this also applies if you're developing a biosimilar for Keytruda, the clinical development is much more expensive than for other biosimilar candidates. Due to its focus on oncology, we're conducting clinical trials. Generally, it's more expensive, due primarily to the very high cost of the reference product. Since we need to procure the reference product for the comparator arm in these trials, it becomes very expensive. There have been budgets allocated for Phase one and Phase three trials. All in all, there are about €120 million of very significant clinical investments behind these programs. Now, with this positive feedback from the EMA on a more streamlined approach, we see an opportunity to reduce the clinical development budget by at least half. And, uh, I think we've opened up for a lot of new interest in this program. And, we're also running an active licensing process. Um, and we're again running on a tight timeline, but we believe we will be able to uphold it. And the ambition here is to close something by the end of October. Ximluci is set to be ready to enter clinical trials in 2025. So that's a brief, kind of operational update. So, with that said, I'm going to hand over to Annette to go through the financials of the quarter.